06/10/2008
ReGen Therapeutics Plc (the ‘Company’) announces that, at the General Meeting of the Company held earlier today, Shareholders passed all the resolutions (including the resolution authorising the Sub-division), as detailed in the circular sent to Shareholders dated 12 September 2008.
The number of New Ordinary Shares in issue following the Sub-division will equal the number of Existing Ordinary Shares currently in issue. The Sub-division will not affect the rights attaching to the Existing Ordinary Shares, other than to alter their nominal value and, in particular, will not affect the voting rights of the holders of Existing Ordinary Shares. The Sub-division will be made by reference to holdings of Existing Ordinary Shares on the register of members as at the close of business on 6 October 2008.
As all Existing Ordinary Shares are being sub-divided, each Shareholder’s percentage holding in the issued share capital of the Company immediately before and after the implementation of the Sub-division will remain unchanged.
New share certificates will not be issued and the existing share certificates will continue to be valid following the Sub-division. Shareholders who hold their shares in the Company through CREST should note that the Company’s ISIN number GB00B28XMY25 will continue to be valid.
Accordingly, application has been made for the 13,068,521 new ordinary shares of 0.01p each arising from the Sub-division to be admitted to trading on AIM. It is expected that admission will be effective and dealings will commence on 7 October 2008.
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish
Tel No 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel No 020 7448 9820
Adrian Duffield/Jon Davies
College Hill Associates
Tel No 020 7457 2020